Aurobindo Pharma. Institutional Equity Research. Sector - Pharmaceuticals. RSec TradEdge India. March 02, 2017
|
|
- Evan Brooks
- 5 years ago
- Views:
Transcription
1 Recommendation Range STOP LOSS Target Aurobindo Pharma Sector - Pharmaceuticals Background & Business Aurobindo Pharma (ARBP) is a mid-sized Indian pharma company with one of the largest product portfolios in the US market. Formulation business contributes ~80% to its total sales, while the contribution of API business stands at ~20%. ARBP s product portfolio is comprises of 6 major therapeutic categories i.e. antibiotics, anti-retrovirals (ARVs), CVS, CNS, gastroenterological, pain management and anti-allergic. US business contributed 45% to its total sales in Q3FY17. Investment Rationale Business Transformation: Overall business mix changed towards high-growth and high-margin formulations complex segment i.e. depot injections, micro-sphere, peptides, ophthalmology, oncology and hormones. Formulations segment revenue (% to sales) increased from 55% in FY12 to 80% in Q3FY17 and we expect this mix to continue in the near future. Contribution of low margin API business (% to sales) has reduced from 44% in FY12 to 20% in Q3FY17. We believe this overall transformation has led to expansion in EBITDA margin (from 13% in FY12 to 23% in FY16). We expect this margin trend to continue, going forward as well (24.8% in FY19E). US Biz business (45% of Sales): US business has been a key growth driver for ARBP s overall revenue growth. The US business contribution has been increased from 25% in FY12 to 45% in Q3FY17, which we expect further increase to 51% in FY19E (CAGR of 19% over FY16-19) driven by launch of niche products in complex generic segment. Management has guided for strong ANDA launches in FY18E (including Meropenem, 2 injectables & Vancomycin etc). ARBP guided for six oral and three injectables in 4QFY17. Natrol acquisition (sales contribution ~US$100mn per year) would further aid its US business. European Biz: Turnaround in ARBP s European business (22% of sales) came ahead of expectations with margin of 6-8% currently (one year ahead of the guidance in FY18E). ARBP plans to transfer 114 products (63 products already transferred to India and supply has started) to India, which we believe would further help in increasing margins. Outlook & Valuation We expect ARBP s US business to drive growth backed by ramp-up in extant products, new launches in complex segment (highgrowth / high-margin). Strong earnings growth, improving returns ratios, strong US product pipeline and comfortable leverage position (capex cycle ends in FY17E) in the next two years augur well for the Company. 1 Year Stock Price Performance Note: *CMP as on March 01, 2017 Key Figure Market Cap ( Rsbn/US$mn ) 397.4/58.4 Current Price 678 Target Price 765 Promoters / Public & Others 51.9/48.1 FY18E P/E (x) 13.8 Risks Revenues CAGR (FY16-18 %) 14.4 Higher-than-expected price erosion/market share in the US. Slower-than-expected turnaround of acquired EU business. PAT CAGR (FY16-18 %) 18.6 Any significant delay in US FDA approvals and regulatory risks. Mar (Rsmn) FY16 FY17E FY18E Key Ratios FY16 FY17E FY18E Revenues 138, , ,735 P/E (x) EBITDA 32,055 37,737 44,525 P/BV (x) EBITDA MARGIN % Adj. PAT 20,480 23,991 28,796 EV/EBITDA (x) ROE (%) Source: Company, RSec Estimates Research Team; Contact: (022) ; rsec.research@rcap.co.in Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 1
2 Recommendation Range STOP LOSS Target NCC Background & Business NCC one of the largest construction companies in India is involved in varied construction works with presence in multiple segments i.e. Transportation, Water & Environment, Buildings, Irrigation and Electrical. The Company has also ventured into Power, Railways, Metals and Mining segments. Further, it is also undertaking works in Roads, Buildings, and Water segments in the Middle East markets. Investment Rationale Well-placed to Capitalize on Huge Opportunities in Infra Space: The Government of India has earmarked US$375bn investment for infrastructure in the next three years. We believe that NCC is best-placed to cash in on imminent opportunities with a balanced presence across infrastructure verticals (10 segments), geographical diversification and prequalification to undertake projects in most verticals. Prudent Approach to Streamline Balance Sheet Started Paying o: NCC has been consistently improving its working capital cycle without compromising its order execution capability and margins over the last couple of years. This along with a prudent divestment of its non-core assets aided NCC to reduce its gross debt from Rs24.7bn in FY14 to Rs18.8bn in FY16 (D/E at 0.5x). Pick-up in Order Book Lends Business Visibility: NCC s current order book stands at strong Rs204bn, which is 2.5x TTM revenue. With the pick-up in government s tendering, NCC has secured order worth Rs93.1bn in FY17E YTD vis-à-vis its own target of Rs120bn. Besides, the Company s L1 position currently stands at over ~Rs30bn. Notably, a large chunk of its order (85%) comes from government, which oers sovereign payment guarantee.. Outlook & Valuation We believe that debt reduction programme and improving operating margins with quality projects have started paying o. Further, the visible ease in working capital cycle and likely pick-up in infrastructure activities will aid NCC in reporting an earning CAGR of ~14% over FY16-FY19E. The stock currently trades at 13.8X FY19E EPS. Risks Slowdown in government s spending on infrastructure development. Political uncertainty. Major deterioration on working capital front. 1 Year Stock Price Performance Sector - Construction Feb-16 Mar-16 Apr-16 May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Note: *CMP as on March 01, 2017 Key Figure Market Cap ( Rsbn/US$mn ) 46.1/6.8 Current Price 83.0 Target Price 94.0 Promoters / Public & Others 19.7/80.3 FY18E P/E (x) 16.3 Revenues CAGR (FY16-18 %) 3.0 PAT CAGR (FY16-18 %) 13.1 Mar (Rs mn) FY16 FY17E FY18E Revenues 83,252 83,443 88,302 Key Ratios FY16 FY17E FY18E EBITDA 7,374 7,383 8,166 P/E (x) EBITDA MARGIN (%) P/BV (x) Adj.PAT 2,228 2,493 2,852 ROE (%) EV/EBITDA (x) Source: Company, RSec Estimates Research Team; Contact: (022) ; rsec.research@rcap.co.in 2
3 Recommendations Summary Open Positions Stock Symbol Sector Reco Date Reco Price CMP SL Target Remarks AUROPHARMA Pharma 02-Mar BUY NCC Construction 02-Mar BUY NIITTECH IT 17-Feb HOLD DABUR FMCG 03-Feb HOLD Closed Positions Stock Symbol Sector Reco Date Reco Price Exit Price Exit Date Return % Remarks NBCC Infrastructure 21-Jun Jul Booked Profit PERSISTENT IT 21-Jun Jul-16 (6.6) Booked Loss SUNPHARMA Pharma 02-Jul Jul Booked Profit PFS NBFC 02-Jul Aug-16 (2.1) Booked Loss CROMPTON Capital Goods 15-Jul Jul Booked Profit UPL Agrochemicals 15-Jul Jul Booked Profit ABFRL Retailing 30-Jul Aug Booked Profit KEC Capital Goods 30-Jul Sep-16 (7.0) Booked Loss MGL Oil-Gas 17-Aug Aug Booked Profit SUNPHARMA Pharma 17-Aug Sep-16 (6.4) Booked Loss INFY IT 01-Sep Sep Booked Profit BAJAJCORP Consumer 01-Sep Oct Booked Profit AUROPHARMA Pharma 16-Sep Sep Booked Profit Continued... 3
4 Closed Positions Stock Symbol Sector Reco Date Reco Price Exit Price Exit Date Return % Remarks NAVKARCORP Logistics 16-Sep Sep-16 (8.0) Booked Loss ABFRL Retailing 03-Oct Oct Booked Profit AMBUJACEM Cement 03-Oct Nov-16 (5.6) Booked Loss ASHOKLEY Auto 17-Oct Oct Booked Profit INFY IT 17-Oct Nov-16 (4.6) Booked Loss TECHM IT 16-Nov Nov Booked Profit CADILAHC Pharma 16-Nov Nov Booked Profit FEDERALBANK Banking 01-Dec Dec-16 (8.5) Booked Loss ASHOKLEY Auto 16-Dec Dec Booked Profit TITAN FMCG 16-Dec Dec Booked Profit CADILAHC Pharma 04-Jan Jan Booked Profit CROMPTON Capital Goods 01-Dec Jan Booked Profit ASIANPAINT FMCG 04-Jan Jan Booked Profit JUBLFOOD FMCG 17-Jan Jan Booked Profit INOXWIND Capital Goods 17-Jan Feb-17 (5.2) Booked Loss HCLTECH IT 03-Feb Feb Booked Profit ABFRL Retailing 17-Feb Feb Booked Profit 4
5 Reliance Securities Limited (RSL), the broking arm of Reliance Capital is one of the India s leading retail broking houses. Reliance Capital is amongst India s leading and most valuable financial services companies in the private sector. Reliance Capital has interests in asset management and mutual funds, life and general insurance, commercial finance, equities and commodities broking, wealth management services, distribution of financial products, private equity, asset reconstruction, proprietary investments and other activities in financial services. The list of associates of RSL is available on the website RSL is registered as a Research Analyst under SEBI (Research Analyst) Regulations, 2014 General Disclaimers: This Research Report (hereinafter called Report ) is prepared and distributed by RSL for information purposes only. The recommendations, if any, made herein are expression of views and/or opinions and should not be deemed or construed to be neither advice for the purpose of purchase or sale of any security, derivatives or any other security through RSL nor any solicitation or oering of any investment /trading opportunity on behalf of the issuer(s) of the respective security(ies) referred to herein. These information / opinions / views are not meant to serve as a professional investment guide for the readers. No action is solicited based upon the information provided herein. Recipients of this Report should rely on information/data arising out of their own investigations. Readers are advised to seek independent professional advice and arrive at an informed trading/investment decision before executing any trades or making any investments. This Report has been prepared on the basis of publicly available information, internally developed data and other sources believed by RSL to be reliable. RSL or its directors, employees, ailiates or representatives do not assume any responsibility for, or warrant the accuracy, completeness, adequacy and reliability of such information / opinions / views. While due care has been taken to ensure that the disclosures and opinions given are fair and reasonable, none of the directors, employees, ailiates or representatives of RSL shall be liable for any direct, indirect, special, incidental, consequential, punitive or exemplary damages, including lost profits arising in any way whatsoever from the information / opinions / views contained in this Report. Risks: Trading and investment in securities are subject to market risks. There are no assurances or guarantees that the objectives of any of trading / investment in securities will be achieved. The trades/ investments referred to herein may not be suitable to all categories of traders/investors. The names of securities mentioned herein do not in any manner indicate their prospects or returns. The value of securities referred to herein may be adversely aected by the performance or otherwise of the respective issuer companies, changes in the market conditions, micro and macro factors and forces aecting capital markets like interest rate risk, credit risk, liquidity risk and reinvestment risk. Derivative products may also be aected by various risks including but not limited to counter party risk, market risk, valuation risk, liquidity risk and other risks. Besides the price of the underlying asset, volatility, tenor and interest rates may aect the pricing of derivatives. Disclaimers in respect of jurisdiction: The possession, circulation and/or distribution of this Report may be restricted or regulated in certain jurisdictions by appropriate laws. No action has been or will be taken by RSL in any jurisdiction (other than India), where any action for such purpose(s) is required. Accordingly, this Report shall not be possessed, circulated and/or distributed in any such country or jurisdiction unless such action is in compliance with all applicable laws and regulations of such country or jurisdiction. RSL requires such recipient to inform himself about and to observe any restrictions at his own expense, without any liability to RSL. Any dispute arising out of this Report shall be subject to the exclusive jurisdiction of the Courts in India. Disclosure of Interest: The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the securities and their respective issuers. None of RSL, research analysts, or their relatives had any known direct /indirect material conflict of interest including any long/short position(s) in any specific security on which views/opinions have been made in this Report, during its preparation. RSL s Associates may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report. RSL, its Associates, the research analysts, or their relatives might have financial interest in the issuer company(ies) of the said securities. RSL or its Associates may have received a compensation from the said issuer company(ies) in last 12 months for the brokerage or non brokerage services.rsl, its Associates, the research analysts or their relatives have not received any compensation or other benefits directly or indirectly from the said issuer company(ies) or any third party in last 12 months in any respect whatsoever for preparation of this report. The research analysts has served as an oicer, director or employee of the said issuer company(ies)?: No RSL, its Associates, the research analysts or their relatives holds ownership of 1% or more, in respect of the said issuer company(ies).?: No Copyright: The copyright in this Report belongs exclusively to RSL. This Report shall only be read by those persons to whom it has been delivered. No reprinting, reproduction, copying, distribution of this Report in any manner whatsoever, in whole or in part, is permitted without the prior express written consent of RSL. RSL s activities were neither suspended nor have defaulted with any stock exchange with whom RSL is registered. Further, there does not exist any material adverse order/judgments/strictures assessed by any regulatory, government or public authority or agency or any law enforcing agency in last three years. Further, there does not exist any material enquiry of whatsoever nature instituted or pending against RSL as on the date of this Report. Important These disclaimers, risks and other disclosures must be read in conjunction with the information / opinions / views of which they form part of. RSL CIN: U65990MH2005PLC SEBI registration no. (Stock Brokers: NSE - INB / INF / INE ; BSE - INB / INF / INE , Depository Participants: CDSL IN-DP IN-DP- SDL , Research Analyst: INH ); AMFI ARN No
Jubilant FoodWorks. Institutional Equity Research. Sector - FMCG. RSec TradEdge India. January 17, 2017
Recommendation Range STOP LOSS Target 825-833 775 960 Jubilant FoodWorks Sector - FMCG Background & Business Jubilant FoodWorks (JFL) a Jubilant Bhartia Group Company incorporated in 1995 is India s largest
More informationCMP* (Rs) 840 Upside/ (Downside) (%) (2.4) Bloomberg Ticker Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6
Event Update November 08, 2017 Market Cap. (Rs bn) 379 Free Float (%) 53 Shares O/S (mn) 451.6 USFDA Warning Letter Entails Further Downside Risk to US Biz The US FDA has issued a Warning Letter (WL) to
More informationCMP* (Rs) 242 Upside/ (Downside) (%) 2. Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630
4QFY17 Result Update June 02,2017 Market Cap. (Rs bn) 157 Free Float (%) 65.6 Shares O/S (mn) 630 Decent Performance to Continue; Maintain Crompton Greaves Consumer Electricals (CGCEL) has delivered a
More informationCMP* (Rs) 417 Upside/ (Downside) (%) 46 Bloomberg Ticker. SUNP IN Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399
Company Update January 22, 2019 Market Cap. (Rs bn) 1,001 Free Float (%) 46 Shares O/S (mn) 2399 Multiple Growth Drivers in Place despite Near-term Headwinds Industries (SUNP) has released an investor
More informationCMP (Rs) 775 Upside/ (Downside) (%) (1.4) Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7
2QFY18 Result Update November 23, 2017 Market Cap. (Rs bn) 11.4 Free Float (%) 35.0 Shares O/S (mn) 14.7 High Order Book Provides Revenue Visibility (PMPL) has delivered a healthy performance in 2QFY18.
More informationCMP* (Rs) 208 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) Free Float (%) 65.6 Shares O/S (mn) 630
1QFY18 Result Update July 28,2017 CMP* (Rs) 208 Bloomberg Ticker CROMPTON IN Market Cap. (Rs bn) 130.6 Free Float (%) 65.6 Shares O/S (mn) 630 Channel De-stocking Impairs Top-line; Recovery Ahead Crompton
More informationNestlé India Outlook Hazy; Valuations Prohibitive
Nestlé India Outlook Hazy; Valuations Prohibitive Nestlé India s net sales, EBITDA and net profit surged by 35% yoy, 67% yoy & 116% yoy to Rs23.5bn, Rs4.5bn & Rs2.7bn, respectively in 3QCY16. This growth
More informationCMP* (Rs) 1,033 Upside/ (Downside) (%) (0.3) Bloomberg Ticker Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452
2QFY18 Result Update October 31, 2017 Market Cap. (Rs bn) 467 Free Float (%) 53 Shares O/S (mn) 452 US Biz to Remain Weak; Maintain Led by weak performance in the US markets, (LPC) has delivered a weak
More informationCMP* (Rs) 166 Upside/ (Downside) (%) 28 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245
3QFY18 Result Update February 05, 2018 CMP* (Rs) 166 Market Cap. (Rs bn) 1,361 Free Float (%) 37.7 Shares O/S (mn) 8,245 Wage Provisioning, Lower in Plant Availability Impede Earnings Growth has delivered
More informationCMP (Rs) 326 Upside/ (Downside) (%) 24. Market Cap. (Rs bn) 21.7 Free Float (%) 42.0 Shares O/S (mn) 67
Management Meet Update March 29, 2019 Market Cap. (Rs bn) 21.7 Free Float (%) 42.0 Shares O/S (mn) 67 Healthy Growth Visibility & Attractive Valuations Augur Well We recently visited (India) Ltd. (AHLU)
More informationCMP* (Rs) 336 Upside/ (Downside) (%) 21 Bloomberg Ticker. MOIL IN Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133
4QFY17 Result Update June 06, 2017 Market Cap. (Rs bn) 45 Free Float (%) 24 Shares O/S (mn) 133 Mixed Quarterly Performance; Volume to Remain Strong has reported a mixed performance in 4QFY17. Its blended
More informationCMP* (Rs) 203 Upside/ (Downside) (%) 23. Market Cap. (Rs bn) 116 Free Float (%) 61 Shares O/S (mn) 572
3QFY19 Result Update February 05, 2019 Market Cap. (Rs bn) 116 Free Float (%) 61 Shares O/S (mn) 572 Strong Performance with Positive Outlook; Maintain (ATL) has reported strong volume performance in 3QFY19.
More informationCMP* (Rs) 346 Upside/ (Downside) (%) 17. Market Cap. (Rs bn) 23 Free Float (%) 42.0 Shares O/S (mn) 67
Consturction India 3QFY18 Result Update February 20, 2018 Market Cap. (Rs bn) 23 Free Float (%) 42.0 Shares O/S (mn) 67 Healthy Show on Higher Margin: Maintain (ACIL) has reported a better-than-expected
More informationCMP* (Rs) 1,464 Upside/ (Downside) (%) 10. Market Cap. (Rs bn) 91 Free Float (%) 55 Shares O/S (mn) 62
1QFY19 Result Update July 25, 2018 Market Cap. (Rs bn) 91 Free Float (%) 55 Shares O/S (mn) 62 Healthy Revenue Growth with Impressive Operating Margin (TEL) has posted a impressive performance in 1QFY19
More informationCMP* (Rs) 161 Upside/ (Downside) (%) 19 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,329 Free Float (%) 30.3 Shares O/S (mn) 8,245
4QFY17 Result Update May 30, 2017 CMP* (Rs) 161 Market Cap. (Rs bn) 1,329 Free Float (%) 30.3 Shares O/S (mn) 8,245 Better Days Ahead s reported earnings declined by 25.0% YoY to Rs20.8bn in 4QFY17 owing
More informationCMP* (Rs) 172 Upside/ (Downside) (%) 11.6 Bloomberg Ticker. NTPC IN Market Cap. (Rs bn) 1,414 Free Float (%) 30.3 Shares O/S (mn) 8,245
1QFY18 Result Update August 03, 2017 CMP* (Rs) 172 Market Cap. (Rs bn) 1,414 Free Float (%) 30.3 Shares O/S (mn) 8,245 Decent Quarterly Performance; Maintain has delivered a decent performance in 1QFY18.
More informationBUY NCC. An Ordinary Quarterly Performance; Maintain BUY. Target Price: Rs98. Institutional Equity Research. 4QFY17 Result Update May 24, 2017
4QFY17 Result Update May 24, 2017 Market Cap. (Rs bn) 46 Free Float (%) 80 Shares O/S (mn) 556 An Ordinary Quarterly Performance; Maintain s reported performance has come in below the expectation as dismal
More informationCMP* (Rs) 1,458 Upside/ (Downside) (%) 10 Bloomberg Ticker. ABB IN Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212
2QCY17 Result Update July 20, 2017 Market Cap. (Rs bn) 309 Free Float (%) 25 Shares O/S (mn) 212 Well-placed in Power T&D Hi-tech Space; Order Book Remains Robust India s revenue rose by 6.0% YoY to Rs23.3bn
More informationTitan Company BUY. Back to Value Zone Validate Rating Upgrade. Institutional Equity Research. November 05, Target Price Rs428.
CMP* (Rs) 369 Market Cap. (Rs bn) 328 Free Float (%) 47 Shares O/S (mn) 888 Titan Company Back to Value Zone Validate Rating Upgrade Titan Company delivered decent performance in 2QFY17 despite reporting
More informationCMP* (Rs) 205 Upside/ (Downside) (%) 12 Bloomberg Ticker. NACO IN Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143
1QFY18 Result Update July 25, 2017 Market Cap. (Rs bn) 29 Free Float (%) 27 Shares O/S (mn) 143 Limited DPD Impact; Upgrade to (NCL) has delivered a decent performance in 1QFY18. Surpassing volume growth,
More informationCMP* (Rs) 360 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5
3QFY18 Result Update January 23, 2018 CMP* (Rs) 360 IN Market Cap. (Rs bn) 38 Free Float (%) 76 Shares O/S (mn) 104.5 Stellar Performance; Fundamentals Remain Intact Central Depository Services () has
More informationHOLD. Nestle. Good Performance Irrespective of GST Pangs. Target Price: Rs6,624. Institutional Equity Research. 2QCY17 Result Update July 27,2017
2QCY17 Result Update July 27,2017 Market Cap. (Rs bn) 657 Free Float (%) 37.3 Shares O/S (mn) 96 Good Performance Irrespective of GST Pangs Nestlé India has reported a good set of numbers for 2QCY17 in
More informationCMP* (Rs) 263 Upside/ (Downside) (%) 7.3. Market Cap. (Rs bn) 635 Free Float (%) 59 Shares O/S (mn) 2,417
2QFY18 Result Update November 01, 2017 Market Cap. (Rs bn) 635 Free Float (%) 59 Shares O/S (mn) 2,417 In-line Performance; Margins to Remain Strong (JSTL) has delivered an in-line performance in 2QFY18
More informationBUY NTPC. Higher Regulated Equity to Aid Profitability; Maintain BUY. Target Price: Rs192. Institutional Equity Research
2QFY18 Result Update November 16, 2017 CMP* (Rs) 174 Market Cap. (Rs bn) 1,438 Free Float (%) 37.0 Shares O/S (mn) 8,245 Higher Regulated Equity to Aid Profitability; Maintain has delivered a decent performance
More informationBUY CDSL. Strong Operating Performance; Maintain BUY. Target Price: Rs435. Institutional Equity Research. 2QFY18 Result Update October 31, 2017
2QFY18 Result Update October 31, 2017 CMP* (Rs) 371 Market Cap. (Rs bn) 39 Free Float (%) 76 Shares O/S (mn) 104.5 Strong Operating Performance; Maintain Central Depository Services () has reported a strong
More informationHOLD ACC. Strong Performance on Better Volume and Firm Realizations. Target Price: Rs1,640. Institutional Equity Research
2QCY17 Result Update July 18,2017 Market Cap. (Rs bn) 328 Free Float (%) 45 Shares O/S (mn) 188 Strong Performance on Better Volume and Firm Realizations reported better-than-estimated performance in 2QCY17
More informationCMP (Rs) 249 Upside/ (Downside) (%) Market Cap. (Rs bn) 25.5 Free Float (%) 29.7 Shares O/S (mn) 102.3
Capital Goods India 3QFY18 Result Update February 08, 2018 Market Cap. (Rs bn) 25.5 Free Float (%) 29.7 Shares O/S (mn) 102.3 Transmission Capex Play; On Right Track continued to deliver a strong performance
More informationBUY. DCB Bank. Improving Capital Consumption to Aid Returns; Maintain BUY. Target Price: Rs202. Institutional Equity Research
3QFY19 Result Update January 17, 219 Market Cap. (Rs bn) 56 Free Float 85 Shares O/S (mn) 39 Improving Capital Consumption to Aid Returns; Maintain continued to deliver a stable set of numbers in 3QFY19
More informationKNR Constructions Robust Performance on Execution Ramp-up
Market Cap. (Rs bn) 18 Free Float (%) 39 Shares O/S (mn) 28 KNR Constructions Robust Performance on Execution Ramp-up KNR Constructions (KNRC) has reported a better-than-expected performance in 1QFY17,
More informationCMP (Rs) 702 Upside/ (Downside) (%) 42 Bloomberg Ticker. JKCE IN Market Cap. (Rs bn) 54 Free Float (%) 42 Shares O/S (mn) 77.3
Company Update January 08, 2019 Market Cap. (Rs bn) 54 Free Float (%) 42 Shares O/S (mn) 77.3 Capacity Expansion on Track; Ease of Funding Concern Augurs Well We have interacted with the senior management
More informationCMP* (Rs) 145 Upside/ (Downside) (%) 32 Bloomberg Ticker BOB IN Market Cap. (Rs bn) 384 Free Float (%) 36 Shares O/S (mn) 2,646
4QFY18 Result Update May 28, 218 Market Cap. (Rs bn) 384 Free Float 36 Shares O/S (mn) 2,646 Improving Outlook; Maintain (BoB) has reported elevated fresh slippages of Rs125.7bn (+123% QoQ and +28% YoY)
More informationCMP* (Rs) 237 Upside/ (Downside) (%) 29 Bloomberg Ticker. APTY IN Market Cap. (Rs bn) 136 Free Float (%) 55.9 Shares O/S (mn) 509
2QFY18 Result Update November 03, 2017 Market Cap. (Rs bn) 136 Free Float (%) 55.9 Shares O/S (mn) 509 Soft Performance Though Indian Operation Improves (ATL) has reported a dismal performance in 2QFY18
More informationCMP* (Rs) 198 Upside/ (Downside) (%) 12. Market Cap. (Rs bn) 61 Free Float (%) 84 Shares O/S (mn) 308
1QFY18 Result Update July 18, 217 Upside/ (Downside) 12 Market Cap. (Rs bn) 61 Free Float 84 Shares O/S (mn) 38 Healthy Core Operating Performance on Key Metrics; Maintain has posted a higher-than-estimated
More informationCMP* (Rs) 189 Upside/ (Downside) (%) (1) Bloomberg Ticker PNB IN Market Cap. (Rs bn) 402 Free Float (%) 38 Shares O/S (mn) 2,128
2QFY18 Result Update November 8, 217 Market Cap. (Rs bn) 42 Free Float 38 Shares O/S (mn) 2,128 Credit Cost to Remain Elevated; Reiterate (PNB) has delivered a healthy performance in 2QFY18. Its PAT rose
More informationCMP* (Rs) 289 Upside/ (Downside) (%) 18. Market Cap. (Rs bn) 30 Free Float (%) 69 Shares O/S (mn) 105
3QFY18 Result Update February 08, 2018 CMP* (Rs) 289 Market Cap. (Rs bn) 30 Free Float (%) 69 Shares O/S (mn) 105 IITS Revenue Continues to Remain Buoyant; Margin Growth Heartening In-line with our estimate,
More informationSonata Software HOLD. Unimpressive Show; IITS Revenue Disappoints. Institutional Equity Research. February 06, Target Price Rs190.
CMP* (Rs) 194 Market Cap. (Rs bn) 20 Free Float (%) 69 Shares O/S (mn) 105 Sonata Software Unimpressive Show; IITS Revenue Disappoints Sonata Software (Sonata) delivered an unimpressive performance in
More informationCMP (Rs) 166 Upside/ (Downside) (%) (1) Bloomberg Ticker Market Cap. (Rs bn) 125 Free Float (%) 37 Shares O/S (mn) 726
2QFY18 Result Update November 8, 217 Market Cap. (Rs bn) 125 Free Float 37 Shares O/S (mn) 726 PSB Recap A Big Positive; but Earnings to Remain Tepid With lower fresh slippages (lowest in last 8 quarters)
More informationCMP* (Rs) 1,424 Upside/ (Downside) (%) 19 Bloomberg Ticker Market Cap. (Rs bn) 268 Free Float (%) 46 Shares O/S (mn) 188
Company Update February 28, 2018 IN Market Cap. (Rs bn) 268 Free Float (%) 46 Shares O/S (mn) 188 In a Sweet Spot Despite Challenges is expected to witness a decent recovery in its operational performance
More informationCMP (Rs) 133 Upside/ (Downside) (%) 35 Bloomberg Ticker. ICEM IN Market Cap. (Rs bn) 41 Free Float (%) 71.6 Shares O/S (mn) 308.1
4QFY18 Result Update May 28, 2018 Market Cap. (Rs bn) 41 Free Float (%) 71.6 Shares O/S (mn) 308.1 Subdued Operating Show on Cost Pressure (ICL) has reported a subdued set of numbers for 4QFY18. Its reported
More informationCMP* (Rs) 301 Upside/ (Downside) (%) 25. Market Cap. (Rs bn) 19.6 Free Float (%) 26 Shares O/S (mn) 65
Infrastructure India Initiating Coverage March 19, 2018 Market Cap. (Rs bn) 19.6 Free Float (%) 26 Shares O/S (mn) 65 Moving towards the Big League (HGI), a newly listed company, is primarily engaged in
More informationKEC International. Recovering from a weak phase. Institutional Equity Research. Order inflow traction remains intact
Jul-14 Aug-14 Sep-14 Oct-14 Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Hindustan Exide Industries Unilever KEC International Recovering from a weak phase KEC International s stock price
More informationKEC International Ltd.
Investment Summary KEC International Ltd. Independent Equity Research March - 2016 Equentis Wealth Advisory Services (P) Ltd Registered Office: 712, Raheja Chambers, Nariman Point, Mumbai 400021 India
More informationKey estimate revision. Financial summary. Year FY15 121, % 16, % FY16E 137, % 20,
: price: EPS: How does our one year outlook change? We maintain rating on Aurobindo post the company s 3QFY16 results. Revenue growth for the quarter was 10% yoy: US sales of $238mn (vs. estimate of $251mn
More informationAurobindo Pharma Ltd.
. Volume No.. I Issue No. 165 Aurobindo Pharma Ltd. March 12, 2018 BSE Code: 524804 NSE Code: AUROPHARMA Reuters Code: ARBN.NS Bloomberg Code: ARBP:IN Aurobindo Pharma Ltd (Auro) is one of the largest
More informationStrides Arcolab. Inline 4Q, recent acquisitions to deepen asset growth. Institutional Equity Research. Strides Arcolab. Pharmaceuticals India
Strides Arcolab Inline 4Q, recent acquisitions to deepen asset growth Strides reported in-line 4QFY15 adjusting for one-time expenses. We remain optimistic on company s business prospects in India, Africa
More informationSonata Software BUY. Laying the Platform for Growth. Institutional Equity Research. December 01, Target Price Rs185.
CMP* (Rs) 157 Market Cap. (Rs bn) 17 Free Float (%) 69 Shares O/S (mn) 15 Sonata Software Laying the Platform for Growth Sonata Software (Sonata) a mid-sized IT firm based in Bangalore caters to Travel,
More informationSamvat 2073 Heading towards New Highs
Samvat 2073 Heading towards New Highs The last Samvat was very challenging and volatile for equity markets as we witnessed sharp cuts in Nifty from 8,000 levels to sub-6,900 during the initial four months,
More informationAurobindo Pharma BUY. Performance Highlights CMP. `580 Target Price `823. 4QFY2017 Result Update Pharmaceutical. Investment Period 12 months
Nov-12 Jun-13 Dec-13 Jul-14 Jan-15 Aug-15 Feb-16 Sep-16 Apr-17 4QFY2017 Result Update Pharmaceutical June 2, 2017 Aurobindo Pharma Performance Highlights Y/E march (` cr) 4QFY17 3QFY17 % chg (QoQ) 4QFY16
More informationAurobindo Pharma ACCUMULATE. Performance Highlights. `780 Target Price CMP `855. 2QFY2019 Result Update Pharmaceutical. Investment Period 12 months
Nov-15 Mar-16 Jul-16 Nov-16 Mar-17 Jul-17 Nov-17 Mar-18 Jul-18 Nov-18 2QFY2019 Result Update Pharmaceutical November 17, 2018 Aurobindo Pharma Performance Highlights Y/E march (` cr) 2QFY19 1QFY19 % chg
More informationDr Reddy s Laboratories
: price: EPS: How does our one year outlook change? We maintain rating on DRRD post the company s 3QFY16 results Revenue growth for the quarter was muted (3% yoy) due to disappointing performances in Russia
More informationGillette India. Institutional Equities. 2QFY19 Result Update BUY. Marketing Investments Mask Improved Top-line Performance
2QFY19 Result Update Gillette India 13 February 2019 Reuters: GILE.NS; Bloomberg: GILL IN Marketing Investments Mask Improved Top-line Performance Gillette India s (GILL) 2QFY19 operating and net earnings
More informationBalkrishna Industries
India I Equities Auto Result Update Change in Estimates Target Reco 13 February 2017 Balkrishna Industries All-round performance, margin guidance reduced; Hold Seventy-five percent of the products of Balkrishna,
More informationKey estimate revision. Financial summary. Year FY16E 29, % 3,583 2, FY17E 26, % 3,478 2,
: price: EPS: How does our one year outlook change? We maintain our negative stance on SKF India due to the absence of significant growth momentum drivers over the medium term. While railways could be
More informationBUY CMP (Rs.) 297 Target (Rs.) 385 Potential Upside 30%
Nov-15 Dec-15 Jan-16 Feb-16 Mar-16 Apr-16 May- Jun-16 Jul-16 Aug-16 Aug-16 Sep-16 Oct-16. Volume No.. I Issue No. 95 Dewan Housing Finance Corporation (DHFL) Nov. 4, 2016 BSE Code: 511072 NSE Code: DHFL
More informationColgate-Palmolive (India)
Result Update Colgate-Palmolive (India) 27 July 218 Reuters: COLG.BO; Bloomberg: CLGT IN Tough Times Continue Colgate-Palmolive (India) or CLGT reported a mixed earnings performance in. Volume and revenue
More informationAurobindo Pharma BUY. Performance Highlights. `708 Target Price CMP `823. 2QFY2018 Result Update Pharmaceutical. Investment Period 12 months
Aug-14 Nov-14 Feb-15 May-15 Aug-15 Nov-15 Feb-16 May-16 Aug-16 Nov-16 Feb-17 May-17 Aug-17 Nov-17 2QFY2018 Result Update Pharmaceutical November 20, 2017 Aurobindo Pharma Performance Highlights Y/E march
More informationABB LTD (INDIA) RESEARCH
RESULTS REVIEW Share Data Market Cap Rs. 168.6 bn Price Rs. 795.80 BSE Sensex 16,741.30 Reuters Bloomberg Avg. Volume (52 Week) ABB.BO ABB IN 0.11 mn 52-Week High/Low Rs. 856.95 / 344 Shares Outstanding
More informationAurobindo Pharma BUY. Performance Highlights CMP. `686 Target Price `877. 3QFY2017 Result Update Pharmaceutical. Investment Period 12 months
3QFY2017 Result Update Pharmaceutical February 23, 2017 Aurobindo Pharma Performance Highlights Y/E march (` cr) 3QFY17 2QFY17 % chg (QoQ) 3QFY16 % chg (yoy) Net sales 3,844 3,714 3.5 3,432 12.0 Other
More informationMARKET RECAP. Instrument Close
INR: THE DOMESTIC CURRENCY COULD REMAIN RANGE BOUND. July 14 th, 2016 MARKET OUTLOOK The Indian Rupee could remain range bound on Thursday. Regional assets remain supported amid expectations global central
More informationPower Mech Projects. Institutional Equities. 2QFY19 Result Update BUY. Strong Order Book Drives Robust Execution
2QFY19 Result Update Power Mech Projects 21 November 218 Reuters: POMP.BO; Bloomberg: POWM IN Strong Order Book Drives Robust Execution Power Mech Projects (PMPL) posted 2QFY19 consolidated revenues of
More informationInstitutional Equities
1QFY19 Result Update Institutional Equities Aurobindo Pharma 13 August 2018 Reuters: ARBP.NS; Bloomberg: ARBP IN One-offs Impact Margin Aurobindo Pharma (APL) reported 1QFY19 revenues of Rs42,503mn which
More informationKey estimate revision. Year CY14 87,383 11,148 6, CY15E 1,20,126 17,838 9,
: price: EPS: How does our one year outlook change? We retain our positive view on EIM on the back of expected improvement in volume and margin at Royal Enfield (RE) and expected revival in VECV on the
More informationKalpataru Power. Rating: Target price: EPS: Rating CMP. Target BUY. Rs Rs.256
: price: EPS: How does our one year outlook change? We expect KPP s revenue (standalone) to grow by 21% y-o-y in FY17E backed by an order book of Rs. 91bn (1.7x FY17E book-to-bill). Both Transmission line
More informationBuy Rating as per Mid Cap 12months investment period
Q2FY18 RESULT UPDATE Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 RETAIL EQUITY RESEARCH Dewan Housing Finance Corporation (DHFL) NBFC BSE CODE: 511072 NSE
More informationJamna Auto Industries
2QFY19 Result Update Institutional Equities Jamna Auto Industries Reuters: JMNA.NS; Bloomberg: JMNA IN Performance Below Expectations; Retain Buy Due To Strong Outlook Jamna Auto s 2QFY19 earnings were
More informationKey estimate revision. Financial summary. Year
: price: EPS: How does our one year outlook change? We retain our positive outlook on WIL and believe that revival in MHCV industry, increasing content per vehicle and opportunity in exports would drive
More informationSimplex Infrastructures
May-14 Jul-14 Aug-14 Sep-14 Nov-14 Dec-14 Jan-15 Mar-15 Apr-15 May-15 India Research Infrastructure May 27, 2015 QUARTERLY REVIEW Bloomberg: SINF IN Reuters: SINF.BO HOLD Working capital ease to improve
More informationBajaj Finance Limited (BFL) NBFC. BUY Rating as per Large Cap 12 months investment period RETAIL EQUITY RESEARCH
COMPANY UPDATE Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 RETAIL EQUITY RESEARCH Bajaj Finance Limited (BFL) NBFC BSE CODE: 500034 NSE CODE: BAJFINANCE Bloomberg
More informationKey estimate revision. Financial summary. Year
: price: ABV: How does our one year outlook change? Retain our positive view on the stock. We continue to believe that SUF is a multi-year compounding opportunity in the asset and home financing segments.
More informationHOLD. Deleveraging story playing out RAMCO CEMENTS. Target Price: Rs 503. Q4 performance
RAMCO S HOLD Target Price: Rs 503 Deleveraging story playing out Ramco Cements total debt reduced by a massive Rs 5 bn to Rs 22 bn in FY16. The company generated total EBITDA of Rs 11.5 bn in FY16 and
More informationAurobindo Pharma. Source: Company Data; PL Research
Sales miss on few approvals, earnings beats on better revenue May 31, 2016 Surajit Pal surajitpal@plindia.com +912266322259 Rating BUY Price Rs786 Target Price Rs943 Implied Upside 2% Sensex 26,668 Nifty
More informationBUY. Efforts on cost cutting paying off RAMCO CEMENTS. Target Price: Rs 435. Key highlights. Key drivers FY15 FY16E FY17E
RAMCO S BUY Target Price: Rs 435 Efforts on cost cutting paying off Q2 EBITDA at Rs 2.8 bn (up 30% YoY) was ahead of our estimates due to lower-than-expected costs. Average costs (excluding freight) declined
More informationPiramal Enterprises Ltd.
Investment Summary Piramal Enterprises Ltd. Independent Equity Research Equentis Wealth Advisory Services (P) Ltd Registered Office: 712, Raheja Chambers, Nariman Point, Mumbai 400021 India Tel: +91 22
More informationAmber Enterprises India Ltd
3QFY2019 Result Update Consumer Durable February 16, 2019 Amber Enterprises India Ltd Performance Update (` cr) 3QFY19 3QFY18 % yoy 2QFY19 % qoq Revenue 388.8 338.4 14.9 226.3 71.8 EBITDA 22.1 24.1 (8.2)
More informationMCX Ltd. Rating: Target price: EPS: Tepid volume growth continues. Target. Rating CMP. Rs. 1,080 SELL. Rs. 1,176
: price: EPS: Tepid volume growth continues 4QFY15 traded volumes in MCX showed a small improvement sequentially whereas declined yoy. FY15 traded Values are at a sever year low. We retain our cautious
More informationInstitutional Equities
4QFY18 Result Update Institutional Equities Atul Auto 30 May 2018 Reuters: ATUL.BO; Bloomberg: ATUL IN Higher Expenses Mar Profitability Atul Auto s (AAL) 4QFY18 earnings missed our expectations on account
More informationGarware Wall Ropes ACCUMULATE. Performance Highlights CMP. `550 Target Price `618. 2QFY2017 Result Update Textile. Investment Period 12 months
2QFY217 Result Update Textile November 16, 216 Garware Wall Ropes Performance Highlights Quarterly Data (`cr) 2QFY17 2QFY16 % yoy 1QFY17 % qoq Revenue 232 214 8.5 225 3.3 EBITDA 4 26 5.9 31 29.4 Margin
More informationVisaka Industries Ltd
Company Update Superior Product Mix & New Age Markets to Aid Growth New investments to aid growth: Visaka continues to give a good set of numbers. YoY EPS grew at 142% aided by a revenue growth of 1.5%
More informationPower Mech Projects. Institutional Equities. 2QFY18 Result Update BUY. Strong Business Scalability Likely; Retain Buy
2QFY18 Result Update Power Mech Projects 23 November 217 Reuters: POMP.BO; Bloomberg: POWM IN Strong Business Scalability Likely; Retain Buy Power Mech Projects (PMPL) posted 2QFY18 consolidated revenues
More informationRamco Cement. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.415. Rs. 360
: price: EPS: How does our one year outlook change? We maintain our positive stance on s (TRCL). The company is one of the largest cement producers in South and remains among the best plays on Southern
More informationGillette India. Institutional Equities. 1QFY18 Result Update
1QFY18 Result Update Institutional Equities Gillette India 14 November 2017 Reuters: GILE.NS; Bloomberg: GILL IN Robust Growth In Operating Margin Gillette India s or GIL s overall top-line performance
More informationRallis India SELL. Performance Highlights. `231 Target Price 189 CMP. 2QFY2018 Result Update Agrichemical. Investment Period 12 months
Jan-12 Jun-12 Nov-12 Apr-13 Sep-13 Feb-14 Jul-14 Dec-14 May-15 Oct-15 Mar-16 Aug-16 Jan-17 Jun-17 Nov-17 2QFY2018 Result Update Agrichemical November 21, 2017 Rallis India Performance Highlights Y/E March
More informationSanofi India ACCUMULATE. Performance Highlights. CMP `4,410 Target Price `4,738. 1QCY2016 Result Update Pharmaceutical. 3-year price chart
1QCY2016 Result Update Pharmaceutical May 5, 2016 Sanofi India Performance Highlights Y/E Dec. (` cr) 1QCY2016 4QCY2015 % chg (qoq) 1QCY2015 % chg (yoy) Net sales 506 522 (3.1) 460 10.1 Other income 64
More informationSanofi India NEUTRAL. Performance Highlights. CMP `4,301 Target Price - 4QCY2016 Result Update Pharmaceutical. Investment Period - 3-year price chart
4QCY2016 Result Update Pharmaceutical March 10, 2017 Sanofi India Performance Highlights Y/E Dec. (` cr) 4QCY2016 3QCY2016 % chg (qoq) 4QCY2015 % chg (yoy) Net sales 552 583 (5.3) 522 5.6 Other income
More informationSkipper Ltd. May 17, Towering high. CMP INR 205 Target INR 238 Result Update - BUY. Company Background. Investment Rationale
May 17, 2017 Skipper Ltd. Towering high CMP INR 205 Target INR 238 Result Update - BUY Key Share Data Face Value (INR) 1.0 Equity Capital (INR Mn) 102.3 Market Cap (INR Mn) 20,979.9 52 Week High/Low (INR)
More informationICICI BANK Ltd. BUY CMP (Rs.) 334 Target (Rs.) 382 Potential Upside 15% Tide set to turn favourably... For private circulation only
Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Volume No.. III Issue No. 160. ICICI BANK Ltd. Feb. 08, 2018 BSE Code: 532174 NSE Code: ICICIBANK Reuters Code:
More informationHDFC Bank Banking BUY RETAIL EQUITY RESEARCH
Q4FY17 RESULT UPDATE May-16 Jun-16 Jul-16 Aug-16 Sep-16 Oct-16 Nov-16 Dec-16 Jan-17 GEOJIT RESEARCH Feb-17 Mar-17 Apr-17 May-17 RETAIL EQUITY RESEARCH HDFC Bank Banking BSE CODE: 500180 NSE CODE: HDFCBANK
More informationBank of Baroda (BOB) Banking. BUY Rating as per Large Cap 12 month investment period RETAIL EQUITY RESEARCH
Q2FY18 RESULT UPDATE Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 RETAIL EQUITY RESEARCH Bank of Baroda (BOB) Banking BSE CODE: 532134 NSE CODE: BANKBARODA
More informationCentury Plyboards (India)
: price: EPS: How does our one year outlook change? We continue to maintain our positive stance on Century Plyboards (CPBI) as it is one of the leading players in the organized plywood market and third
More informationIndian Oil Corporation Ltd.
Nov-14 Dec-14 Jan-15 Feb-15 Mar-15 Apr-15 May-15 Jun-15 Jul-15 Aug-15 Sep-15 Oct-15 Nov-15 Dec-15 Jan-16 Feb-16 February 12, 2016 COMPANY RESULTS REPORT REVIEW Analyst Sudeep Anand +91-22-4322 1190 sudeep.anand@idbicapital.com
More informationHDFC Bank. BUY CMP (Rs.) 1,807 Target (Rs.) 2,000 Potential Upside 11%
Oct-16 Nov-16 Dec-16 Jan-17 Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17. Volume No.. I Issue No. 147 HDFC Bank Oct. 31, 2017 BSE Code: 500180 NSE Code: HDFCBANK Reuters Code: HDBK.NS
More informationState Bank of India (SBI) Banking. BUY Rating as per Large Cap 12 month investment period RETAIL EQUITY RESEARCH
COMPANY UPDATE Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Nov-18 Dec-18 Jan-19 Feb-19 Mar-19 RETAIL EQUITY RESEARCH State Bank of India (SBI) Banking BSE CODE: 500112 NSE CODE: SBIN Bloomberg
More informationHCL Technologies. Rating: Target price: EPS: Target CMP. Rating. Rs. 826 REDUCE. Rs.760
: price: EPS: How does our one year outlook change? HCLT registered a strong quarter with revenues growing at 6.5% qoq (4% qoq organic) including $40m contribution from Volvo, after a disappointing show
More informationAhluwalia Contracts (India)
May-14 Jul-14 Aug-14 Sep-14 Oct-14 Dec-14 Jan-15 Feb-15 Apr-15 May-15 India Research Infrastructure May 22, 215 QUARTERLY REVIEW Bloomberg: AHLU IN Reuters: AHLU.BO BUY Better performance ahead ACIL posted
More informationAxis Bank Ltd. For private circulation only. Volume No.. III Issue No October 08, 2018
Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18 Sep-18 Oct-18 Volume No.. III Issue No. 188. Axis Bank Ltd. October 08, 2018 BSE Code: 532215 NSE Code: AXISBANK Reuters Code:
More informationBlue Star Ltd BUY. Performance Update. CMP Target Price `703 `867. 1QFY2019 Result Update Cons. Durable. 3-year price chart.
Aug-15 Oct-15 Dec-15 Feb-16 Apr-16 Jun-16 Aug-16 Oct-16 Dec-16 Jan-17 Apr-17 May-17 Jul-17 Sep-17 Nov-17 Jan-18 Mar-18 May-18 Jul-18 1QFY2019 Result Update Cons. Durable August 10, 2018 Blue Star Ltd Performance
More informationITC. Institutional Equities. 4QFY18 Result Update. Tracking Expectations ACCUMULATE. Sector: FMCG CMP: Rs286 Target Price: Rs290 Upside: 1%
4QFY18 Result Update Institutional Equities ITC 17 May 2018 Reuters: ITC.NS; Bloomberg: ITC IN Tracking Expectations ITC s growth in 4QFY18 was modest and in line with expectations. On the revenue side,
More informationLarsen & Toubro Ltd.
Feb-17 Mar-17 Apr-17 May-17 Jun-17 Jul-17 Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Volume No.. III Issue No. 163. Larsen & Toubro Ltd. February 26, 2018 BSE Code: 500510 NSE Code: LT Reuters Code:
More informationITC Ltd. BUY CMP (Rs.) 304 Target (Rs.) 336 Potential Upside(%) 11% Valuation: Investment Rationale. For private circulation only
Aug-17 Sep-17 Oct-17 Nov-17 Dec-17 Jan-18 Feb-18 Mar-18 Apr-18 May-18 Jun-18 Jul-18 Aug-18. Volume No.. I Issue No. 186 ITC Ltd September 21, 2018 BSE Code: 500875 NSE Code: ITC Reuters Code: ITC.NS Bloomberg
More informationAmbuja Cements. Rating: Target price: EPS: Rating CMP. Target BUY. Rs.225. Rs. 195
: price: EPS: How does our one year outlook change? We maintain our positive stance on ACEM. We expect ACEM to be a big beneficiary of the restructuring of LafargeHolcim s global operations. The long pending
More information